Inappropriate Sinus Tachycardia (IST)
Definition
IST is defined as a sinus heart rate >100 bpm at rest (mean 24-hour HR >90 bpm, not due to primary causes) associated with distressing symptoms of palpitations.
Key Concepts
Epidemiology
- Prevalence ~1.2% using a Holter-based definition in a middle-aged population (7/604 patients)
- No known mortality; believed to be chronic; natural history and rate of spontaneous improvement unclear sources/POTS-IST-VVS-HRS-2015 (rating: high)
Pathophysiology
- Incompletely understood; proposed mechanisms: increased sinus node automaticity, β-adrenergic hypersensitivity (β-adrenergic receptor antibodies sensitising receptors in some patients), decreased parasympathetic activity, impaired neurohumoral modulation sources/POTS-IST-VVS-HRS-2015 (rating: high)
- IST is triggered by physiologic AND emotional stresses — this distinguishes it from POTS, which is induced only by orthostatic stress sources/POTS-IST-VVS-HRS-2015 (rating: high)
- Rarely associated with tachycardia-mediated cardiomyopathy sources/POTS-IST-VVS-HRS-2015 (rating: high)
Diagnosis
- Thorough history and physical examination to exclude primary causes of sinus tachycardia (thyroid disease, medications, drugs, hypovolemia, POTS)
- 12-lead ECG to confirm sinus rhythm and exclude other atrial tachyarrhythmias
- 24h Holter to confirm mean 24-hour HR >90 bpm (required for diagnosis)
- Cardiovascular autonomic reflex tests (deep breathing, Valsalva, cold face test) and treadmill testing not recommended routinely due to unproven clinical utility sources/POTS-IST-VVS-HRS-2015 (rating: high)
Treatment
- No long-term placebo-controlled RCT evidence for any treatment
- Significant psychosocial distress is nearly ubiquitous; close attention and effective communication improve outcomes
- Lifestyle changes should be discussed early with all patients
- Ivabradine (most evidence-based): Blocks If current; 5–7.5 mg BID; slows HR 25–40 bpm; eliminated symptoms in 70% of patients in a small crossover RCT (n=21, 12 weeks); combination with metoprolol may be safe and effective; was not US-approved at time of guideline sources/POTS-IST-VVS-HRS-2015 (rating: high)
- Beta-blockers: Not usually effective and can cause adverse effects sources/POTS-IST-VVS-HRS-2015 (rating: high)
- Other therapies with limited/no evidence: fludrocortisone, volume expansion, compression stockings, phenobarbital, clonidine, psychiatric evaluation, exercise training, erythropoietin
- Sinus node modification/ablation: Not recommended for routine care; reasonable primary success rates but high symptom recurrence rate; significant complications (requirement for permanent pacing, transient or permanent phrenic nerve paralysis, transient SVC syndrome); ablation may not relieve all IST-associated symptoms; may be offered in highly selected circumstances or as part of research protocols only sources/POTS-IST-VVS-HRS-2015 (rating: high)
ACC/AHA/HRS 2015 SVT Guideline Recommendations for IST (Section 3.2)
Definition (2015 guideline)
- Sinus HR >100 bpm at rest + mean 24h HR >90 bpm not due to physiological responses or primary causes (hyperthyroidism, anemia); associated with debilitating symptoms sources/svt-aha-2015 (rating: very high)
- Diagnosis of exclusion: must rule out hyperthyroidism, anemia, dehydration, drugs/stimulants, anxiety, POTS, structural heart disease
Treatment (Class-Based)
- Class I/C-LD: Evaluate and treat reversible causes first (most important step)
- Class IIa/B-R: Ivabradine — inhibits If channel → reduces sinus node pacemaker rate → HR reduction without other hemodynamic effects; 2.5–7.5 mg BID; reduces daytime HR from 98 to 85 bpm in crossover RCT; significant symptom relief including complete resolution in many; superior to metoprolol in 1 observational study; phosphenes in 3% (transient); well tolerated in large RCTs (SHIFT/BEAUTIFUL) sources/svt-aha-2015
- Class IIb/C-LD: Beta blockers — modest HR reduction; dose limited by hypotension; generally less effective than ivabradine
- Class IIb/C-LD: Combination beta blocker + ivabradine — may be considered in refractory IST; ivabradine (7.5 mg BID) added to metoprolol (95 mg daily) resolved symptoms in all patients in small study; monitor for excessive bradycardia
- Sinus node modification/ablation: Reasonable ONLY for highly symptomatic patients who fail medications; procedural success 76–100% but IST recurrence up to 27%, overall symptomatic recurrence 45% at follow-up; significant complications: pacemaker requirement, phrenic nerve injury (right hemidiaphragm paralysis), SVC syndrome; risks may outweigh benefits; must inform patient fully sources/svt-aha-2015
Key Clinical Points from 2015 Guideline
- Lowering HR may NOT relieve all symptoms in IST
- Tachycardia-mediated cardiomyopathy secondary to IST is extremely rare
- IST must be distinguished from focal AT arising from superior crista terminalis (abrupt onset/termination) and sinus node reentrant tachycardia
- Exercise training may be beneficial but evidence is limited
- No specific acute treatment recommendations exist for IST
ESC 2019 Updates on IST
Pathophysiology addition (ESC 2019): Gain-of-function mutation in HCN4 channel (pacemaker current) reported in familial IST; evolving evidence for IgG anti-beta receptor antibodies in some patients sources/svt-esc-2019 (rating: very high)
IST not associated with TCM — ESC 2019 explicitly confirms this (relevant because TCM can be caused by other forms of SVT) sources/svt-esc-2019
ESC 2019 Recommendations for IST:
- Evaluate and treat reversible causes: I/C (consistent with AHA 2015)
- Ivabradine alone or in combination with beta-blocker: IIa/B — consistent with AHA 2015; ESC 2019 notes that blockade of If may perturb baroreceptor feedback loop, increasing sympathetic activity — theoretically concerning for remodelling/pro-arrhythmia; co-administration with beta-blocker preferred when possible; avoid in pregnancy/breastfeeding; CYP3A4 substrate (avoid with ketoconazole, verapamil, diltiazem, clarithromycin, grapefruit) sources/svt-esc-2019
- Beta-blockers: IIa/C (upgraded from IIb in some prior framings; may require doses causing intolerable fatigue) sources/svt-esc-2019
- Catheter ablation: NOT recommended for routine IST management (ESC 2019 explicit) — evidence "limited and disappointing" from small observational studies sources/svt-esc-2019
Contradictions / Open Questions
- Pathophysiology incompletely understood; HCN4 mutation accounts for rare familial IST; anti-beta receptor antibodies in subset — no unified mechanistic model
- Ivabradine evidence limited to small crossover RCTs (n=21 largest); ESC 2019 notes theoretical concern about baroreceptor feedback perturbation with chronic ivabradine monotherapy — recommends co-administration with beta-blocker when possible sources/svt-esc-2019
- Whether sinus node ablation can reliably and durably relieve all IST-associated symptoms remains unresolved; symptom recurrence high — ESC 2019 explicitly states catheter ablation should not be considered as part of routine management sources/svt-aha-2015 sources/svt-esc-2019
- Guideline concordance on ivabradine: HRS 2015 (small RCT, off-label), AHA 2015 SVT guideline (IIa/B-R), ESC 2019 (IIa/B) — all consistent; however, no definitive large RCT exists sources/svt-aha-2015 sources/POTS-IST-VVS-HRS-2015 sources/svt-esc-2019
- Beta-blocker class in IST: AHA 2015 IIb/C-LD vs ESC 2019 IIa/C — modest discordance; ESC 2019 upgraded possibly to reflect clinical utility in dose-limited settings sources/svt-aha-2015 sources/svt-esc-2019
Connections
- Related to concepts/SVT-Management — IST is addressed as a sinus tachyarrhythmia subtype in the 2015 SVT guideline
- Related to concepts/POTS — both present with sinus tachycardia; POTS triggered by orthostatic stress only; IST by any physiologic or emotional stress; 24h Holter and tilt test can distinguish them
- Related to concepts/Vasovagal-Syncope — shared autonomic dysfunction context; IST and VVS can coexist
- Related to concepts/Biological-Pacemaker — sinus node If current (HCN channels) as therapeutic target